TipRanks
Advertisement
Advertisement

TTRX Stock Latest News

Turn Therapeutics Updates GX-03 Program and Pipeline Outlook
Company AnnouncementsTurn Therapeutics Updates GX-03 Program and Pipeline Outlook
5d ago
8K
TTRX
Seven new option listings on October 2nd
PremiumThe Fly
Seven new option listings on October 2nd
10d ago
GENB
HOST
Turn Therapeutics initiated with a Buy at Lucid Capital
PremiumThe Fly
Turn Therapeutics initiated with a Buy at Lucid Capital
18d ago
TTRX
Turn Therapeutics to Present Atopic Dermatitis Strategy
PremiumCompany Announcements
Turn Therapeutics to Present Atopic Dermatitis Strategy
1M ago
8K
TTRX
Turn Therapeutics Names Robert Redfield Chief Scientific Officer
PremiumCompany Announcements
Turn Therapeutics Names Robert Redfield Chief Scientific Officer
1M ago
8K
TTRX
Turn Therapeutics appoints Redfield as Chief Scientific Officer
PremiumThe FlyTurn Therapeutics appoints Redfield as Chief Scientific Officer
1M ago
TTRX
Turn Therapeutics announces publication of peer-reviewed research on GX-03
Premium
The Fly
Turn Therapeutics announces publication of peer-reviewed research on GX-03
2M ago
TTRX
Turn Therapeutics Reports Unregistered Cashless Warrant Share Issuance
Premium
Company Announcements
Turn Therapeutics Reports Unregistered Cashless Warrant Share Issuance
2M ago
8K
TTRX
Turn Therapeutics Raises $1.35M Through Private Placement
PremiumCompany Announcements
Turn Therapeutics Raises $1.35M Through Private Placement
2M ago
8K
TTRX
Turn Therapeutics reports Q2 EPS (20c) vs (5c) last year
PremiumThe Fly
Turn Therapeutics reports Q2 EPS (20c) vs (5c) last year
2M ago
TTRX
Turn Therapeutics Updates GX-03 Investor Presentation and Pipeline
PremiumCompany Announcements
Turn Therapeutics Updates GX-03 Investor Presentation and Pipeline
3M ago
8K
TTRX
PremiumCompany Announcements
Turn Therapeutics advances GX-03 Phase 2 eczema program
3M ago
8K
TTRX
Turn Therapeutics announces final Stage 2 design of atopic dermatitis program
PremiumThe FlyTurn Therapeutics announces final Stage 2 design of atopic dermatitis program
3M ago
TTRX
Turn Therapeutics Highlights GX-03 Phase 2 Atopic Dermatitis Data
Premium
Company Announcements
Turn Therapeutics Highlights GX-03 Phase 2 Atopic Dermatitis Data
4M ago
8K
TTRX
Turn announces interim analysis findings from Phase 2 trial of GX-03
Premium
The Fly
Turn announces interim analysis findings from Phase 2 trial of GX-03
4M ago
TTRX
Turn Therapeutics Reports Positive Interim Phase 2 GX-03 Data
PremiumCompany Announcements
Turn Therapeutics Reports Positive Interim Phase 2 GX-03 Data
4M ago
8K
TTRX
Turn Therapeutics announces peer-reviewed article on GX-03
PremiumThe Fly
Turn Therapeutics announces peer-reviewed article on GX-03
5M ago
TTRX
Turn Therapeutics highlights GX-03 preclinical data in dermatitis
PremiumCompany Announcements
Turn Therapeutics highlights GX-03 preclinical data in dermatitis
5M ago
8K
TTRX
Turn Therapeutics CEO to Present at Jefferies Conference
PremiumCompany Announcements
Turn Therapeutics CEO to Present at Jefferies Conference
5M ago
8K
TTRX
Turn Therapeutics Appoints Former FDA Chief to Lead GX-03
PremiumCompany AnnouncementsTurn Therapeutics Appoints Former FDA Chief to Lead GX-03
5M ago
8K
TTRX
Turn appoints Hahn as Executive Clinical, Regulatory Lead for GX-03
Premium
The Fly
Turn appoints Hahn as Executive Clinical, Regulatory Lead for GX-03
5M ago
TTRX
Turn Therapeutics reports Q1 EPS (3c) vs. (1c) last year
Premium
The Fly
Turn Therapeutics reports Q1 EPS (3c) vs. (1c) last year
5M ago
TTRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >